Revenue Breakdown
Composition ()
No data
Revenue Streams
Charles River Laboratories International Inc (CRL) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is DSA, accounting for 59.8% of total sales, equivalent to $600.68M. Other significant revenue streams include RMS and Manufacturing. Understanding this composition is critical for investors evaluating how CRL navigates market cycles within the Biotechnology & Medical Research industry.
Profitability & Margins
Evaluating the bottom line, Charles River Laboratories International Inc maintains a gross margin of 30.96%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 12.09%, while the net margin is -27.79%. These profitability ratios, combined with a Return on Equity (ROE) of -4.36%, provide a clear picture of how effectively CRL converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, CRL competes directly with industry leaders such as ICLR and BAH. With a market capitalization of $8.79B, it holds a significant position in the sector. When comparing efficiency, CRL's gross margin of 30.96% stands against ICLR's 22.32% and BAH's 51.03%. Such benchmarking helps identify whether Charles River Laboratories International Inc is trading at a premium or discount relative to its financial performance.
